| 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|
| 营业收入(元) | |||
| 代理产品(元) | 108,816,469.06 | 257,929,084.09 | 127,965,462.22 |
| 呼吸系统类(元) | 50,745,625.55 | 227,247,739.94 | 93,851,313.72 |
| 抗生素类(元) | 238,317,811.75 | 995,037,152.60 | 504,688,725.63 |
| 消化系统类(元) | 533,658,292.78 | 818,287,223.54 | 338,826,790.43 |
| 其他类(元) | 126,453,610.28 | 316,167,962.19 | 174,435,003.28 |
| 营业成本(元) | |||
| 代理产品(元) | 80,208,639.13 | - | 91,988,132.87 |
| 呼吸系统类(元) | 37,056,959.84 | - | 57,173,619.74 |
| 抗生素类(元) | 161,611,476.17 | 698,072,897.21 | 376,303,531.43 |
| 消化系统类(元) | 171,674,511.83 | 310,312,667.06 | 127,564,730.13 |
| 其他类(元) | 73,412,752.93 | 202,481,378.33 | 91,358,868.04 |
| 毛利(元) | |||
| 代理产品(元) | 28,607,829.93 | - | 35,977,329.35 |
| 呼吸系统类(元) | 13,688,665.71 | - | 36,677,693.98 |
| 抗生素类(元) | 76,706,335.58 | 296,964,255.39 | 128,385,194.20 |
| 消化系统类(元) | 361,983,780.95 | 507,974,556.48 | 211,262,060.30 |
| 其他类(元) | 53,040,857.35 | 113,686,583.86 | 83,076,135.24 |
| 毛利率(%) | |||
| 代理产品(%) | 26.29 | - | 28.11 |
| 呼吸系统类(%) | 26.98 | - | 39.08 |
| 抗生素类(%) | 32.19 | 29.84 | 25.44 |
| 消化系统类(%) | 67.83 | 62.08 | 62.35 |
| 其他类(%) | 41.94 | 35.96 | 47.63 |
| 收入构成(%) | |||
| 代理产品(%) | 10.29 | 9.86 | 10.32 |
| 呼吸系统类(%) | 4.80 | 8.69 | 7.57 |
| 抗生素类(%) | 22.53 | 38.06 | 40.71 |
| 消化系统类(%) | 50.44 | 31.30 | 27.33 |
| 其他类(%) | 11.95 | 12.09 | 14.07 |
| 毛利构成(%) | |||
| 代理产品(%) | 5.36 | 0.00 | 7.26 |
| 呼吸系统类(%) | 2.56 | 0.00 | 7.40 |
| 抗生素类(%) | 14.36 | 32.33 | 25.92 |
| 消化系统类(%) | 67.78 | 55.30 | 42.65 |
| 其他类(%) | 9.93 | 12.38 | 16.77 |